Short Interest in Akari Therapeutics, Plc (NASDAQ:AKTX) Drops By 94.3%

Akari Therapeutics, Plc (NASDAQ:AKTX) saw a significant decrease in short interest in April. As of April 15th, there was short interest totalling 600 shares, a decrease of 94.3% from the March 31st total of 10,500 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average trading volume of 12,000 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Akari Therapeutics in a research report on Wednesday. They issued a “sell” rating for the company.

Akari Therapeutics Stock Performance

Shares of AKTX stock remained flat at $1.19 on Thursday. 3,902 shares of the stock traded hands, compared to its average volume of 12,181. The business has a 50-day simple moving average of $1.82 and a 200 day simple moving average of $2.63. Akari Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $5.50.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Akari Therapeutics stock. Omnia Family Wealth LLC raised its stake in shares of Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 87,628 shares of the biopharmaceutical company’s stock after acquiring an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned approximately 1.55% of Akari Therapeutics worth $273,000 at the end of the most recent quarter. 5.06% of the stock is owned by institutional investors.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.